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Part IV
Basic Considerations of the Psoralens
HISTORICAL ASPECTS OF METHOXSALEN AND OTHER FUROCOUMARINS*
THOMAS B. FITZPATRICK, M.D., Ph.D. AND M. A. PATHAK, B.Sc. (Hons.), M.Sc. (Tech.)
Some of man's earliest research efforts were
concerned with attempts to restore the normal
skin color to scattered, pigment-less areas con-
sidered to be leprosy, although most of which
were probably vitiligo. In the Indian sacred book
Atharva Veda, which dates back to 1400 B.C. or
earlier, the "cure" of leprosy and leukoderma
(vitiligo) with certain black seeds together with
Bringartga (Eeclipta prostata), Indravaruni,
(Coloc path), and turmeric (Curcuma longa)
has been described in detail. The importance of
the problem is illustrated by the following ode
to one of the plants used, described in the
Atharva Veda (1, 2).
Born by night art thou, 0 plant,
Dark, black, sable, do thou,
That art rich in color, stain
This leprosy and white gray spots.
Even color is the name of thy mother,
Even color is the name of thy father.
Thon 0 plant producest even color
Render this (spot) to even color.
The plant alluded to is not precisely known, but
when one reads other ancient Indian medical
literature such as A.stanga-Hridaya Samhita
by Vagbhata, or edicine, a large German
encyclopedia of Indo-Iranian studies (3), it would
appear that the most widely used plant was Bava-
chee, a species containing psoralen.
In the Bower manuscript translated by A. F.
R. Hoernele (4) which deals with manuscript
remains of Buddhist literature found in Eastern
Turkestan and the studies of medicine in ancient
India (about 200 A.D.), the cure of leukoderma
with the plant known as "Vasuchika" (said to be
an old form of Bavachee or Psoralea corytijolia)
has been distinctly mentioned. In "Sino-Iranica"
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written by Be thold Laufer, (5) a drug by the
name pu-ku-c (bu-kut-tsi) which had been
identified as Psoralea corylifolia by the Maci
collaborator in the Kai Pao pen Tscao (A.D.
968—976) of the Sung period, is mentioned as a
treatment of leukoderma. The author comments
that the plant name Bwa-ku-Si or Ba-ku-c,
popularly but erroneously written as po ku c,
is not of Chinese but Indian origin. It resembles
the Sanskrit, Va-ku-ci, (Vasuchika) which is
Psoratea corylifolia and which had been used
by the Hindus in the Ayurvedic system of medi-
cine. This plant contains a photodynamically
active furocoumarin, psoralen.
Another important plant, Ammi majus, a weed
found in the Nile Valley, has been employed for
centuries as a "cure" for leukoderma. Ibn El
Bitar, who lived in the thirteenth century, gave a
description of the usefulness of this plant for
leukoderma in his famous book, "Mofradat El-
Adwiya" (6). This plant was used by "Ben-
Shocib" a Berberian tribe in the Northwestern
African desert.
The modern period of psoralen research began
in 1938 when Kuske investigated "phytophoto-
dermatitis", a bullous eruption appearing on the
areas of the skin which have been in contact
with certain plants and subsequently exposed to
sunlight (7). He obtained pure compounds by
extraction of oil of bergamot (bergapten), mas-
terwort or Peucedenum ostruthium (oxypeucede-
nm), and figs (ficusin or psoralen).
Extensive research on psoralens began in
1941 in the laboratories of Fahmy and his
group at the University of Cairo, Egypt. Fahmy
observed that some Egyptian herb doctors were
using a gray-green powder called "Atrillal" for
the treatment of vitiligo. It was distributed
through only one or two dealers who would not
reveal its nature. Fahmy later ascertained that
"Atrillal" powder was obtained from the fruits
of a weed growing along the Nile delta called
Ammi majus L. Fahmy and Abu-Shady in 1947
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isolated three crystalline compounds which they
believed were the active ingredients of the crude
powder (8). These were found to be furocou-
marins and were named from the plant from
which they were obtained (Ammi majus L.):
ammoidin, ammidin and majudin. This was an
unfortunate selection of names for two of the
compounds had already been known. Ammoidin,
or 8-methoxypsoralen, had been isolated in 1911
from a different plant source (9) and synthesized
in 1933 by Spath (10). Majudin, or 5-methoxy-
psoralen, was a well-known constituent of oil of
bergamot which had long been used in the per-
fume industry.
Fahmy then engaged an excellent young Egyp-
tian dermatologist, El Mofty, to carry out a
clinical trial of the three compounds in the treat-
ment of vitiligo. The results were encouraging
(11), and shortly afterward two of the com-
pounds, 8-methoxypsoralen and 8-isoamylene-
oxypsoralen, were marketed by an Egyptian
firm in Cairo. This firm distributed tablets and
a topical liquid containing the two drugs. Con-
firmation of El Mofty's results were reported in
France (12, 13). However, some difficulty was
encountered in introducing the drugs into the
United States, and only one pharmaceutical
firm started clinical trials of 8-methoxypsoralen
(generic name, methoxsalen) in this country.
In 1951, Pinkus began a study of topical methox-
salen in the treatment of vitiligo (14). Lerner,
Denton and Fitzpatrick (1952) at the University
of Michigan used the drug orally in nine vitiligo
patients with moderate success (15). In the
course of this study, a curious effect was noted in
two of the vitiligo patients. These patients, who
were brothers engaged in farming, noted that they
were able to tolerate sunlight on the vitiligo
areas much better than before the treatment.
In addition, three albinos, who were then given
methoxsalen, commented on an increased toler-
ance to sunlight. Fitzpatrick and Lerner (1954)
had the opportunity to treat a physician's wife
with vitiligo at the University of Oregon Med-
ical School in November, 1952. The patient
declared that ingestion of methoxsalen before
exposure to sunlight substantially enhanced the
tanning response of her normal-appearing skin.
From 1952—54, Fitzpatrick and Lerner used
methoxsalen orally in the treatment of 110
vitiligo patients and extended the testimonial-
type evidence of increased sun tolerance of
vitiligo skin following treatment (16). In addition,
36 normal persons claimed increased tanning and
decreased sunburn while using 20 mg. of methox-
salen daily. Because of the testimonial type of
evidence, it was decided to carry out controlled
studies of the apparent augmented tanning and
increased solar tolerance following oral methox-
salen. The results of earlier controlled experi-
ments have been reported (17). Meanwhile,
Musajo (1955) in Italy had reported the relative
activity of many furocoumarins and coumarin
derivatives applied topically to human skin (18).
It became apparent that methoxsalen or one
of the furocoumarins might possibly be de-
veloped as an oral drug to increase the tolerance
of human skin to sunlight. Because of the im-
portant basic and clinical implications of this
hypothesis, a fairly extensive research effort
was begun in a few medical centers on the bo-
tanical sources of furocoumarins, their mecha-
nism of action, their toxicity in animals and
man, the development of high intensity, mono-
chromatic ultraviolet sources, and the effect of
furocoumarins on the incidence of solar or ultra-
violet-induced skin cancer in man and mice. As a
result, considerable information is now available
on some of the phases mentioned above, although
many aspects remain to be clarified.
The notion that an orally ingested compound
could alter the tolerance of man to solar radiation
appears to be following the pattern of hypothe-
ses which, according to William James, pass
through three classic stages:
First, a new hypothesis is attacked as absurd;
Second, it is admitted to be true but obvious
and insignificant;
Finally, it is seen to be so important that its
adversaries claim that they themselves dis-
covered it.
The furocoumarin hypothesis is at present in
the first of these stages with symptoms of the
second stage having begun in a few quarters.
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